CC-223 is a potent and selective inhibitor of the mechanistic target of rapamycin (mTOR) pathway, specifically targeting mTORC1 and mTORC2 complexes. It is primarily used in cancer research due to its ability to suppress tumor cell growth, proliferation, and survival. By inhibiting mTOR signaling, CC-223 disrupts protein synthesis and cell cycle progression in malignant cells, making it a candidate for treating various solid tumors and hematologic malignancies. It has shown activity in preclinical models of breast cancer, prostate cancer, and other advanced solid tumors, particularly in tumors with dysregulated PI3K/AKT/mTOR signaling pathways. CC-223 is also being investigated for its potential to overcome resistance to other targeted therapies, including hormone therapies and kinase inhibitors. Due to its oral bioavailability and favorable pharmacokinetic profile in early studies, CC-223 has been evaluated in clinical trials to assess its safety, tolerability, and efficacy either as a monotherapy or in combination with other anticancer agents. Its development supports ongoing efforts to expand targeted treatment options in oncology.